News
Google News: Sofosbuvir demonstrates high response rate in interferon-free ...
[aidsmap] - Edward Gane from Auckland City Hospital in New Zealand described the latest data from the phase 2 ELECTRON trial, which is evaluating sofosbuvir in various interferon-free regimens. As background, Gane noted that ELECTRON investigators initially
Gilead Sciences shares rise after interim data from phase 2 hep C trial
www.proactiveinvestors.com
[Proactive Investors USA & Canada] - “These results indicate that adding GS to sofosbuvir-based regimens may enhance SVR rates, potentially offering HCV genotype 1 infected patients a convenient 12-week course of oral therapy,” said Professor Edward Gane, the principal investigator
Gilead annuncia un tasso di risposta virologica sostenuta del
www.informazione.it
[informazione.it (Comunicati Stampa)] Professore Edward Gane, Epatologo e Vice Direttore dell'Unità Trapianti di fegato della Nuova Zelanda (New Zealand Liver Transplant Unit) presso l'Ospedale di Auckland City in Nuova Zelanda, nonché sperimentatore principale dello studio ELECTRON.
Royal Society of NZ recognises achievements of researchers | Scoop...
www.scoop.co.nz
Outstanding New Zealand researchers have been awarded prestigious medals at the Royal Society of New Zealand Research Honours event, held in Wellington on...
sorted by relevance / date